Precision Bio rises after gene editing data: BMO upgrades (update)
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...
bovnews2d
Breaking News: Why Precision BioSciences (DTIL) Is Dominating the Stock Market Today
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
Advancements in Precision BioSciences’ Gene Editing Platform Bolster Buy Rating
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly Buys 2,113 Shares
CFO John Alexander Kelly purchased 2,113 shares of Precision BioSciences stock in a transaction dated Friday, December 27th.
Yahoo Finance1d
Precision BioSciences, Inc. (DTIL)
DURHAM, N.C., January 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Precision BioSciences shares soar on promising gene editing trial results
Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...
Nasdaq3d
Precision Biosciences' ECUR-506 Achieves Complete Response In OTC Deficiency Patient
(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...
Strong Buy Recommendation for Precision BioSciences: Promising Clinical Data and Favorable Valuation
BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...
Investing2d
Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward
On Friday, BMO Capital Markets analysts upgraded Precision BioSciences Inc . (NASDAQ: NASDAQ:DTIL) stock rating from Market Perform to Outperform, setting a price target of $34.00. This optimistic ...